Obesity is one of the most important public health problems facing the world today. Gene expression studies applied to fat depots from obese subjects have provided important clues about the pathophysiology of adipose tissue. The data collected in this thesis show that the synthesis of fatty acids (lipogenesis) is decreased in the adipose tissue of obese subjects, and describe the behavior of a new lipogenic factor. We also demonstrate that subcutaneous fat (beneath the skin of the buttocks, thighs and abdomen) is characterized by a greater responsiveness to thyroid hormones than the visceral (around the omentum, the intestines and the perirenal areas), and describe the increased activity of enzymes that activate thyroid hormones in adipose tissue of obese patients and the effects on the metabolism. According to these results, the local activation of thyroid hormone and the ability to synthesize fat are altered in adipose tissue from obese patients, and indicate significant differences between visceral and subcutaneous adipose tissue depots. / La obesidad es uno de los problemas de salud pública más importante. Los estudios de expresión aplicados a los depósitos de grasa en sujetos obesos han aportado importantes indicios sobre la fisiopatología del tejido adiposo. Los datos recogidos en esta tesis doctoral demuestran que la síntesis de grasa (lipogénesis) está disminuida en el tejido adiposo del paciente obeso, y describen el comportamiento de un nuevo factor lipogénicos. Se demuestra además que el tejido adiposo subcutáneo (situado bajo la piel de las nalgas , muslos y abdomen) está caracterizado por una mayor capacidad de respuesta a las hormonas tiroideas respecto al adiposo visceral (alrededor del epiplón, los intestinos y las áreas perirrenal) y se describe un incremento en la actividad de las enzimas que activan las hormonas tiroideas en el tejido adiposo del paciente obeso y los posibles efectos de esta eventualidad sobre el metabolismo. Según los resultados recopilados en esta tesis doctoral, la activación local de hormonas tiroideas y la capacidad para sintetizar acidos grasos del tejido adiposo del paciente obeso están alteradas, e indican importantes diferencias entre los depósitos de grasa visceral y subcutáneo. / L’obesitat és un dels problemes de salut pública més important. Els estudis d'expressió aplicats als dipòsits de greix en subjectes obesos han aportat importants indicis sobre la fisiopatologia del teixit adipós. Les dades recollides a aquesta tesi doctoral demostren que la síntesis de greix (lipogènesis) està disminuïda al teixit adipós del pacient obès, i descriuen el comportament d'un nou factor lipogènic. Es demostra, a més a més, que el teixit adipós subcutani (situat sota la pell de les natges, cuixes i abdomen) està caracteritzat per una major capacitat de resposta a les hormones tiroidees respecte a l'adipós visceral (al voltant de l’epipló, els intestins i las àrees perirenals) i es descriu un increment en l’activitat dels enzims que activen les hormones tiroidees al teixit adipós del pacient obès i els possibles efectes d'aquesta eventualitat sobre el metabolisme. Segons els resultats recopilats a aquesta tesi doctoral, l’activació local d'hormones tiroidees i la capacitat per sintetitzar greixos del teixit adipós del pacient obès estan alterades, i indiquen importants diferències entre els dipòsits de greix visceral i subcutani.

Adipose tissue (AT) expansion and remodeling that maintains healthy function relies on stromal preadipocytes capable of differentiating into new adipocytes (adipogenesis). During chronic positive energy balance, a relative deficit in adipogenesis, from either a decrease in preadipocyte number or their capacity to differentiate, leads to excessive adipocyte hypertrophy and AT dysfunction. AT contains macrophages whose number and activation state is dynamically regulated with changes in AT mass. This study aims to investigate the effect of macrophage-secreted factors on preadipocyte survival. To assess the effect of macrophage-secreted factors on preadipocytes, murine 3T3-L1 preadipocytes or human primary preadipocytes were incubated with macrophage-conditioned medium (MacCM), prepared from either murine (J774A.1, RAW264.7, bone marrow-derived) or human (THP-1, monocyte-derived) macrophage models, respectively. MacCM inhibited preadipocyte apoptosis and activated pro-survival signaling in both preadipocyte models. Inhibition of PDGFR, Akt, or ERK1/2 reduced the pro-survival effect of MacCM in 3T3-L1 preadipocytes. Inhibition of reactive oxygen species (ROS) generation, or enhancement of ROS clearance, reduced MacCM-dependent 3T3-L1 preadipocyte survival. Whereas anti-inflammatory activated macrophages retained the ability to prevent preadipocyte apoptosis, pro-inflammatory activated macrophages did not. TNF-α immunoneutralization restored the survival activity of pro-inflammatory MacCM on 3T3-L1 preadipocytes. These studies reveal a novel pro-survival effect of MacCM on preadipocytes, and identify signaling molecules (PDGF, Akt, ERK1/2, and ROS) that underlie this action. Macrophage activation was found to regulate the pro-survival activity of MacCM. These in vitro cell culture studies are consistent with a model in which the extent of preadipocyte apoptosis in vivo may determine preadipocyte number and the ability of AT to expand while maintaining healthy function during chronic positive energy balance.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / A baixa relação de ômega-6/ômega-3 esta relacionada com propriedades benéficas para a saúde óssea. No entanto, a dieta rica nestes compostos pode levar a obesidade. Adipócitos e osteoblastos derivam de células progenitoras comuns, e o consumo de óleo de canola pode ter ação adipogênica e osteogênica. Nosso objetivo foi avaliar a adiposidade abdominal, insulina e estrutura óssea em ratos tratados com dieta contendo baixa relação ômega-6/ômega-3, proveniente do óleo de canola. Após desmame, os ratos foram divididos em grupos alimentados com dieta normocalórica: Controle (S) e experimental (C), contendo 7ml/100g de óleo de soja ou de canola e grupos tratados com dieta rica em lipídios: Controle (7S) ou hiperlipídico contendo 19ml/100g de óleo de soja (19S) ou de canola (19C), até completarem 60 dias de idade. Os dados foram significativos com P<0,05. No primeiro modelo, o grupo C apresentou redução de: Massa e área do adipócito intra-abdominal; Colesterol; Insulina; Densidade mineral (DMO) e massa óssea total e na coluna vertebral; Massa do fêmur; Espessura da diáfise; DMO do fêmur e das vértebras lombares e radiodensidade da cabeça do fêmur. No segundo modelo, os grupos 19S e 19C apresentaram maior ingestão calórica, densidade corporal, massa de gordura intra-abdominal, e maior massa e comprimento do fêmur e da coluna lombar. O grupo 19S apresentou maior área e menor número de adipócitos da região retroperitoneal. Glicose e a insulina foram aumentadas no grupo 19C vs. 7S. A tomografia do fêmur revelou maior radiodensidade na região proximal e da coluna lombar, no grupo 19C. Sugerimos que a quantidade e o tipo de lipídio consumido, após o desmame, induzem não somente o desenvolvimento corporal e os depósitos de gordura, além de afetarem a resistência insulínica e a saúde óssea / The lower ratio of omega-6 to omega-3 polyunsaturated fatty acids is associated with healthy bone properties. However, fat diets can induce obesity. Adipocytes and osteoblasts derive from a common progenitor, and canola oil intake may have an adipogenic and osteogenic effect. Our objective was to evaluate the intra-abdominal adiposity, insulin and bone growth in rats fed diet containing lower ratio of omega-6 to omega-3, provided in canola oil. After weaning, rats were divided into groups fed with normocaloric diet: control (S) and experimental (C), containing 7ml/100g soybean or canola oil, respectively and groups fed with fat diet: control (7S) or fat diets containing 19ml/100g soybean oil (19S) or canola oil (19C), until they 60 days old. Differences were considered significant with P<0,05. In normocaloric diet model, C group showed a significant reduction in: Intra-abdominal fat mass; Area of adipocyte; Cholesterol; Insulin; Total body and spine bone mineral content and bone area; Femur mass; Width of the diaphysis; Femur and lumbar vertebrae bone mineral density and radiodensity of femoral head. To high-fat diet model, 19S and 19C groups showed higher energy intake, body density growth, intra-abdominal fat mass and higher femur mass and, lumbar vertebrae mass and length. 19S showed higher area and lower number of retroperitoneal adipocytes. Glucose and insulin were significantly increased in 19C compared to 7S group. Computed tomography of femur revealed higher radiodensity in proximal femoral epiphysis and lumbar vertebrae of 19C. We suggest that the amount and the source of fat used in the diet, after weaning, induce not only the body and fat depots growth, besides affecting the insulin resistance and the bone health

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / A baixa relação de ômega-6/ômega-3 esta relacionada com propriedades benéficas para a saúde óssea. No entanto, a dieta rica nestes compostos pode levar a obesidade. Adipócitos e osteoblastos derivam de células progenitoras comuns, e o consumo de óleo de canola pode ter ação adipogênica e osteogênica. Nosso objetivo foi avaliar a adiposidade abdominal, insulina e estrutura óssea em ratos tratados com dieta contendo baixa relação ômega-6/ômega-3, proveniente do óleo de canola. Após desmame, os ratos foram divididos em grupos alimentados com dieta normocalórica: Controle (S) e experimental (C), contendo 7ml/100g de óleo de soja ou de canola e grupos tratados com dieta rica em lipídios: Controle (7S) ou hiperlipídico contendo 19ml/100g de óleo de soja (19S) ou de canola (19C), até completarem 60 dias de idade. Os dados foram significativos com P<0,05. No primeiro modelo, o grupo C apresentou redução de: Massa e área do adipócito intra-abdominal; Colesterol; Insulina; Densidade mineral (DMO) e massa óssea total e na coluna vertebral; Massa do fêmur; Espessura da diáfise; DMO do fêmur e das vértebras lombares e radiodensidade da cabeça do fêmur. No segundo modelo, os grupos 19S e 19C apresentaram maior ingestão calórica, densidade corporal, massa de gordura intra-abdominal, e maior massa e comprimento do fêmur e da coluna lombar. O grupo 19S apresentou maior área e menor número de adipócitos da região retroperitoneal. Glicose e a insulina foram aumentadas no grupo 19C vs. 7S. A tomografia do fêmur revelou maior radiodensidade na região proximal e da coluna lombar, no grupo 19C. Sugerimos que a quantidade e o tipo de lipídio consumido, após o desmame, induzem não somente o desenvolvimento corporal e os depósitos de gordura, além de afetarem a resistência insulínica e a saúde óssea / The lower ratio of omega-6 to omega-3 polyunsaturated fatty acids is associated with healthy bone properties. However, fat diets can induce obesity. Adipocytes and osteoblasts derive from a common progenitor, and canola oil intake may have an adipogenic and osteogenic effect. Our objective was to evaluate the intra-abdominal adiposity, insulin and bone growth in rats fed diet containing lower ratio of omega-6 to omega-3, provided in canola oil. After weaning, rats were divided into groups fed with normocaloric diet: control (S) and experimental (C), containing 7ml/100g soybean or canola oil, respectively and groups fed with fat diet: control (7S) or fat diets containing 19ml/100g soybean oil (19S) or canola oil (19C), until they 60 days old. Differences were considered significant with P<0,05. In normocaloric diet model, C group showed a significant reduction in: Intra-abdominal fat mass; Area of adipocyte; Cholesterol; Insulin; Total body and spine bone mineral content and bone area; Femur mass; Width of the diaphysis; Femur and lumbar vertebrae bone mineral density and radiodensity of femoral head. To high-fat diet model, 19S and 19C groups showed higher energy intake, body density growth, intra-abdominal fat mass and higher femur mass and, lumbar vertebrae mass and length. 19S showed higher area and lower number of retroperitoneal adipocytes. Glucose and insulin were significantly increased in 19C compared to 7S group. Computed tomography of femur revealed higher radiodensity in proximal femoral epiphysis and lumbar vertebrae of 19C. We suggest that the amount and the source of fat used in the diet, after weaning, induce not only the body and fat depots growth, besides affecting the insulin resistance and the bone health

A descoberta de aminopeptidase regulada por insulina (IRAP), a qual hidrolisa peptídeos como ocitocina e vasopressina e é receptora de angiotensina IV, destaca a importância do estudo do envolvimento de peptidases na função endócrina do adipócito. Estudos recentes detectaram alterações das atividades de aminopeptidase neutra e de dipeptidil peptidase IV (DPPIV) no plasma e no hipotálamo e hipocampo na obesidade induzida por glutamato monossódico (MSG). A presente tese propôs (i) a existência de atividades aminopeptidásicas ácida (APA), básica (APB), neutra insensível (APM) e sensível à puromicina (PSA), metionil (MetAP) e DPPIV, além da já conhecida (leucil (LAP)/cistil (CAP)/IRAP), nas frações de membrana plasmática (FM) e de alta (HDM) e baixa (LDM) densidade microssomal de adipócitos isolados do depósito de gordura retroperitoneal; (ii) que suas atividades catalíticas, expressões gênicas e tráfego subcelular seriam diferenciados entre obesos induzidos por MSG, submetidos ou não à privação alimentar e em animais controle sadios, submetidos ou não a privação alimentar; (iii) e influenciadas por insulina, angiotensina II, angiotensina IV e vasopressina. A existência de todas essas aminopeptidases no adipócito foi demonstrada, sendo a APM a que apresenta maior Vmax e maior eficiência catalítica e a APA a maior afinidade. Os animais obesos apresentaram aumento do diâmetro médio dos adipócitos e aumento do lipócrito, caracterizando hipertrofia adipocítica, enquanto os controles privados de alimento tiveram um aumento no número de adipócitos e aumento no lipócrito, caracterizando hiperplasia adipocítica. Pela primeira vez, um perfil variado de atividades aminopeptidásicas distribuídas em diferentes compartimentos subcelulares do adipócito é evidenciado juntamente com a demonstração de diferenças no padrão de distribuição destas atividades entre os ratos obesos e sadios, privados ou não de alimento. Dentre as novas aminopeptidases detectadas no adipócito não há nenhuma com a característica clássica de IRAP. No geral, as alterações das atividades catalíticas nas diferentes situações sob estudo mostram o envolvimento dessas novas aminopeptidases na regulação endócrina do balanço energético (provavelmente via ação hidrolítica sobre angiotensina II e vasopressina) sob modulação por angiotensina IV (APB, APM, DPPIV, LAP/IRAP, MetAP e PSA em animais controle sadios e APB em animais controle privados de alimento), angiotensina II (APB e PSA nos animais obesos) e vasopressina (APB nos animais obesos privados de alimento; e influenciadas em seu tráfego subcelular por angiotensina II (CAP, DPPIV e LAP/IRAP) e angiotensina IV (LAP/IRAP). O tráfego subcelular da conhecida atividade CAP/IRAP mostrou-se suscetível à insulina e vasopressina / The discovery of insulin-regulated aminopeptidase (IRAP), which hydrolyzes peptides such as oxytocin and vasopressin and is an angiotensin IV receptor, highlights the importance of the involvement of peptidases in the endocrine function of adipocyte. Recent studies have detected changes in aminopeptidase activities of neutral aminopeptidase and dipeptidyl peptidase IV (DPPIV) in the plasma and in the hypothalamus and hippocampus of rats with obesity induced by monosodium glutamate (MSG). The present thesis proposes (i) the existence of acid (APA), basic (APB), neutral insensitive (APM) and puromycin sensitive (PSA) aminopeptidases, methionyl aminopeptidase (MetAP) and dipeptidyl peptidase IV (DPPIV), besides the well-known cystyl (CAP) / leucine aminopeptidase (LAP) / IRAP) in plasma membrane (MF) and in high (HDM) and low (LDM) density microsomes of isolated adipocytes from retroperitoneal fat pad; (ii) that their catalytic activities, gene expression and subcellular trafficking were different among MSG-induced obese and healthy control rats (food deprived or not); (iii) and influenced by insulin, angiotensin II and IV, and vasopressin. The existence of all these adypocite aminopeptidases was demonstrated. APM has a highest Vmax and catalytic efficiency, while APA has a highest substrate affinity. The obese animals have increased mean diameter of adipocytes and lipocrit, characterizing hypertrophy, while the food deprived rats had an increased number of adipocytes and lipocrit, characterizing hyperplasia. For the first time, a profile of varied aminopeptidases activities distributed in different subcellular compartments of adipocyte is evidenced together with the demonstration of differences in the distribution pattern of these activities among the obese and healthy rats, food deprived or not. Among these novel aminopeptidases detected in adipocytes there is no one with the classical characteristic of IRAP. In general, changes on catalytic activities in these different situations show the involvement of these novel aminopeptidases in the endocrine regulation of energy balance (probably via hydrolytic action on angiotensin II and vasopressin) under modulation by angiotensin IV (APB, APM, DPPIV, LAP/IRAP, MetAP and PSA in healthy animals and APB in food deprived healthy animals), by angiotensin II (APB and PSA in obese) and by vasopressin (APB in food deprived obese animais); and under influence of by angiotensin II (CAP, DPPIV, LAP/IRAP) and angiotensin IV (LAP/IRAP) on their subcellular trafficking. Subcellular trafficking of the well-known CAP/IRAP was susceptible to insulin and vasopressin

Abstract Bone remodelling occurs in humans throughout life, therefore bone is continuously renewed to better respond to changes in weightbearing circumstances. Bone remodelling is extremely vulnerable during fracture healing and integration of prostheses into the surrounding bone. Bone remodelling is a complex system in which many growth factors, cytokines and enzymes, which are essential for the differentiation of osteoblasts and osteoclasts, are involved. Some widely used drugs can affect this sensitive system of remodellation in unexpected manner. Painkillers such as cyclooxygenase (COX) inhibitors have been demonstrated in animal studies to interfere with fracture healing and a few retrospective clinical studies confirm these observations. Bisphosphonates (BP), main target of which is the bone resorbing osteoclast, have been suggested to be the drug of choice to improve periprosthetic bone density and thus prevent aseptic loosening of implants. The exact mechanism of action of clodronate (CLO), a non-amino-BP, which was selected for the study, has not been clarified thus far. In order to gain a deeper understanding of the role of the COX enzyme in the differentiation of osteoblasts we studied human mesenchymal stem cell (hMSC) cultures in the presence of different COX-inhibitors; indomethacine, parecoxib and NS398, a specific COX-2 inhibitor. We used the liposome encapsulated CLO metabolite (AppCCl2p) to study in detail the mechanism of BP induced apoptosis in osteoclast. The effects of different BPs CLO, pamidronate (PAM) and zoledronic acid (ZOL), on the differentiation of osteoblasts and osteoclasts were tested in vitro. The optimal concentration for in situ CLO rinsing in clinical study was found. Finally, the effects of in situ and per oral CLO on the periimplant bone density and integration of prostheses were studied in vivo. All tested COX-inhibitors significantly inhibited osteoblast differentiation from hMSCs and stimulated the differentiation of adipocytes. It was also demonstrated that AppCCl2p inhibits mitochondrial function by a mechanism that involves competitive inhibition of ADP/ATP translocase. In the comparison of BPs, ZOL seemed to posses the properties of both non-amino- and amino-BPs and it thus belongs to a new class of BPs. Peroral and in situ CLO seemed to have different mechanisms of action. Peroral CLO delayed the integration of prosthesis to the bone and increased peri-implant osteolysis while is situ CLO accelerated integration. In conclusion, we can alter normal bone remodellation during fracture healing and prosthesis integration. On the other hand, we can also improve the circumstances for the integration of implant to the surrounding bone by in situ BP rinsing, thus creating a better environment for bone ingrowth. / Tiivistelmä Läpi elämän luustossa tapahtuu uudelleenmuotoutumista, remodelaatiota, jonka seurauksena luu pystyy paremmin vastaamaan muuttuneisiin kuormitusolosuhteisiin. Remodelaatioprosessi on hyvin haavoittuvainen murtuman luutumisen aikana sekä proteesin kiinnittyessä ympäröivään luuhun. Luun remodelaatioon osallistuvat kasvutekijät, sytokiinit ja entsyymit, jotka puolestaan ovat välttämättömiä osteoblastien ja osteoklastien erilaistumiselle. Monet lääkeaineet voivat yllättävällä tavalla vahingoittaa tätä herkkää remodelaatiosysteemiä. Kipulääkkeet, kuten syklo-oksygenaasi (COX) estäjät, voivat häiritä murtuman luutumista aikaisempien eläintöiden ja muutamien retrospektiivisten potilastutkimusten mukaan. Lisäksi bisfosfonaatit, joiden päävaikutuskohde on luuta hajoittava osteoklasti, voisivat olla lupaavia lääkkeitä myös parantamaan proteesia ympäröivän luun laatua ja siten estämään aseptista implantin irtoamista. Tutkimuksen yhtenä tarkoituksena oli selvittää klodronaatin, ensimmäisen polven typpi-ryhmää sisältämättömän bisfosfonaatin tarkka vaikutusmekanismi. Viljelemällä ihmisen luuytimen kantasoluja indometasiinia, parekoksibia tai spesifistä COX-2 estäjää NS 398:a, sisältävässä kasvatusliuoksessa selvitettiin COX-entsyymin merkitys osteoblastien erilaistumiselle. Liposomien sisälle pakattua klodronaatin metaboliittia (AppCCl2p) käytettiin tutkittaessa millä vaikutusmekanismilla klodronaatti aiheuttaa osteoklastien apoptoosin. Bisfosfonaattien; klodronaatin, pamidronaatin ja tsoledronaatin vaikutusta osteoklastien ja osteoblastien erilaistumiseen tutkittiin soluviljelmämallissa ja määritettiin kliinisessä potilastyössä paikallisesti käytettävän klodronaattiliuoksen pitoisuus. Lopuksi potilastyössä selvitettiin paikallisen klodronaattihuuhtelun ja suun kautta annostellun klodronaatin vaikutus proteesia ympäröivän luun tiheyteen ja proteesin kiinnittymiseen ympäristöönsä. Tutkimukseen valitut COX-estäjät vähensivät ihmisen kantasolujen erilaistumista osteoblasteiksi ja lisäsivät erilaistumista rasvasoluiksi. Lisäksi todettiin, että AppCCl2p estää mitokondrioissa tapahtuvaa hengitystä estämällä ADP/ATP-vaihtajan toiminnan, saaden aikaan solukuoleman. Vertailtaessa bisfosfonaatteja, tsoledronaatilla vaikutti olevan sekä ensimmäisen, että kolmannen polven (sisältää typpi-ryhmän) bispfosfonaattien vaikutuksia, joten tsoledronaatti kuuluu aivan uuteen bisfosfonaattiryhmään. Potilastutkimuksessa suun kautta ja paikallisesti reisiluun ytimeen annostellulla klodronaatilla oli täysin erilainen vaikutus. Suun kautta syötynä klodronaatti hidasti proteesin kiinnittymistä ja aiheutti osteolyysiä. Sen sijaan paikallinen klodronaatti nopeutti merkittävästi proteesin kiinnittymistä ympäröivään luuhun. Näiden tutkimustulosten perusteella voidaan olettaa, että COX-estäjät, samoin kuin peroraalinen bisfosfonaatti, voivat tahattomasti häiritä luun remodelaatiota.

Les ressources marines constituent un réservoir considérable de substances actives, en particulier, de peptides bioactifs appelés cryptides. Les cryptides, qui sont initialement dissimulés au cœur des protéines, sont libérés lors de la digestion ou lors de procédés protéolytiques industriels. Ces cryptides pourraient procurer des bienfaits physiologiques ou assurer une protection contre des pathologies telles que celles du syndrome métabolique. Dans ce contexte, nous nous sommes intéressés à l’action de certains cryptides marins sur des cibles impliquées dans l’hypertension, le diabète et l’obésité. Nous avons pu mettre en évidence que certains cryptides pouvaient cibler in vitro plusieurs facteurs de risques associés au développement des anomalies du syndrome métabolique. / Marine products represent an important source of active substances, in particular bioactive peptides called cryptides. Cryptides are hidden within the sequence of a parent protein and are released during digestion or industrial proteolytic processes. These cryptides could provide physiological benefit or protection against diseases such as those of metabolic syndrome. In this context, we investigated the action of some marine cryptides on hypertension, diabetes and obesity. We demonstrated that some cryptides can target in vitro several factors associated with the development of metabolic syndrome.

LYL1 (Lymphoblastic leukemia-derived sequence 1) est un facteur de transcription basic hélice-boucle-hélice (bHLH) exprimé dans les lymphocytes B, les cellules myéloïdes et les cellules endothéliales (CE). Les souris déficientes pour Lyl1 (Lyl1-/-) sont viables et chez la souris adulte, LYL1 a un rôle majeur dans la maturation des vaisseaux sanguins nouvellement formés et dans le contrôle de la perméabilité vasculaire basale, suggérant l'importance de LYL1 dans le maintien de la quiescence et/ou stabilisation des CE. Les vaisseaux sanguins représentent une barrière entre le sang et le tissu conjonctif. Ils peuvent également jouer le rôle de niche vasculaire contenant des progéniteurs des différentes cellules murines (par exemple, des cellules hématopoïétiques, des cellules β-pancréatiques, des cellules neuronales, des cellules hépatiques et des cellules adipeuses). Les deux tissus adipeux, blancs et bruns (WAT et BAT), sont très vascularisés. Jusqu'à présent, rien n'était connu sur le rôle de LYL1 dans le tissu adipeux. Les résultats présentés dans cette thèse montrent que l'augmentation significative du poids corporel des mâles Lyl1-/- par rapport aux souris sauvages (WT), sous régime normal, n'est pas associée à des troubles métaboliques. Ils présentent également un poids plus élevé de tissus adipeux (WAT et BAT) et de plus grandes gouttelettes lipidiques. In vivo, la perte de Lyl1 accélère le processus de différenciation des cellules souches adipeuses (CSA), puisque les adipocytes blancs et bruns sont matures et actifs plus tôt. De plus, les CSA sont moins nombreuses dans les tissus adipeux, ce qui confirme que la perte de Lyl1 favorise la différenciation des CSA vers adipocytes matures. Nous avons également démontré que Lyl1 est exprimée dans les CSA et les pré-adipocytes, suggérant un rôle direct dans LYL1 dans la différenciation adipocytaire. D'autre part, les vaisseaux des WAT des souris Lyl1-/- sont mal recouverts de cellules murales et plus perméables, suggérant que la niche vasculaire des tissus adipeux pourrait être perturbée. Sous alimentation riche en graisses (HFD), le poids corporel et le poids du tissu adipeux sont plus faibles chez les souris Lyl1-/- par rapport à WT. De plus les souris Lyl1-/- présentent de plus petites gouttelettes lipidiques que les WT, sous HFD. Ces résultats préliminaires, suggèrent que les souris Lyl1-/- pourraient être protégées contre l'obésité induite par l'alimentation. Cependant d'autres expériences sont nécessaires pour valider ces résultats. Il existe probablement un mécanisme de compensation qui se met en place chez les souris Lyl1-/- sous HFD. Ce travail a démontré que, sans Lyl1, la différenciation adipocytaire est accélérée et que la niche vasculaire adipocytaire est perturbée. / LYL1 (Lymphoblastic leukemia-derived sequence 1) is a basic helix-loop-helix (bHLH) transcriptional factor, which is expressed in B lymphocytes, myeloid cells and endothelial cells (EC). Lyl1 deficient (Lyl1-/-) mice are viable and in adult mice, LYL1 has an active role in the maturation of newly formed blood vessels and is also involved in the control of basal vascular permeability, suggesting that LYL1 is required for the maintenance of EC quiescence and stabilization. Blood vessels provide a barrier between connective tissue and blood. They also have been described as “vascular niche” containing progenitors of different murine cells (e.g. hematopoietic cells, pancreatic β-cells, neuronal cells, liver cells and adipose cells). Both white and brown adipose tissues (WAT and BAT) are highly vascularized. Up to now, nothing was known concerning the role of LYL1 in adipose tissue. The results presented in this thesis revealed that the significant increase in body weight of Lyl1-/- males compared to their wild type (WT) littermates under chow diet is not due to any metabolic disorders. They also showed higher adipose tissue weights (BAT and WAT) and bigger lipid droplets. In vivo Lyl1 deficiency cause early differentiation process of adipose stem cells (ASCs) since both white and brown adipocytes are mature and active faster. In addition, ASCs are less numerous in Lyl1-/- adipose tissues, which confirm that Lyl1 deficiency favors the differentiation of ASCs towards mature adipocytes. We also demonstrated that Lyl1 is expressed both in ASCs and pre-adipocytes, suggesting a direct role of LYL1 in adipocyte differentiation. On the other hand, the vessels in Lyl1-/- WAT are poorly covered with mural cells and more permeable, proposing that adipose stem cell vascular niche could be disturbed. Under high fat diet (HFD), total body weight and adipose tissue weight are lower in Lyl1-/- mice compared to WT. Moreover smaller lipid droplets were observed in Lyl1-/- mice under HFD. These preliminary results suggest that Lyl1-/- mice could be protected from diet-induced obesity. However more experiments are needed to validate these results. Probably there is a compensatory type of mechanism going on under HFD in Lyl1-/- mice. This work demonstrated that under Lyl1 deficiency adipocyte differentiation process becomes faster and adipose tissue vascular niche could be disturbed.

Metabolic pathways in adipose tissue affect the whole-body energy homeostasis. De novo lipogenesis and futile metabolic cycling based on lipolysis and fatty acid re-esterification which is engaged in regulation of fatty acid level in bloodstream are occuring there. These processes are partly regulated by nuclear receptor PPARγ. Mitochondrial biogenesis and oxidative phosphorylation in adipocytes are controlled by interacting of PPARγ with transcriptional coactivators PGC-1α and PGC-1β. The aims of this thesis were to find out whether PGC-1β is connected with regulation of futile cycling and de novo lipogenesis in white adipose tissue and also how specific inactivation of PGC-1β gene in adipose tissue affects phenotype of mice during short-term cold exposure or treatment based on high fat diet enriched by n-3 polyunsaturated fatty acids in combination with mild calorie restriction. The results show that inactivation of PGC-1β probably does not affect futile cycling based on lipolysis and fatty acid re-esterification. In mice with PGC-1β ablation compensation in weight of brown adipose tissue was observed as well as increase in the gene expresion of nuclear receptors PPAR, transcriptional coactivator PGC-1α and UCP1 during cold exposure. Even though the inactivation of PGC-1β in brown adipose tissue...

Internalization and trafficking of ligand-receptor complex rely on a particular set of proteins, e.g. small GTPase protein Rab5 and its activators called guanine nucleotide exchange factors. Rab5-activating protein 6 (RAP6), a Vps9-containing protein, may participate in Rab5-mediated insulin signaling and receptor trafficking. A dicarbonyl compound methylglyoxal was found to alter insulin signaling in preadipocytes. This dissertation aimed to investigate the association of RAP6 activity on 3T3-L1 preadipocyte differentiation and those driven by methylglyoxal. Overexpression of RAP6 inhibited preadipocyte differentiation, Ser473-phosphorylation of Akt1, and expression of adipogenic marker PPARγ, but not C/EBPα. Methylglyoxal (10 µM) increased preadipocyte differentiation, proliferation and expression of PPARγ, C/EBPα and p-Akt1-Ser473, but appeared to be neutralized by RAP6 overexpression. The findings suggest that RAP6 may be a key modulator in regulating the stimulatory effect of methylglyoxal on preadipocyte differentiation. The associations of predominant methylglyoxal-derived adduct, methylglyoxal hydroimidazolone 1 (MGH1), with selected risk factors of chronic diseases in Black participants with and without type 2 diabetes (n=234 controls and n=254 cases) were also investigated. Only in individuals with diabetes, MGH1 levels were positively associated with fasting plasma glucose (B=0.240, p=0.037), homocysteine (B=0.355, p=0.014) and triglyceride (B=0.190, p=0.049). Being African Americans with type 2 diabetes was associated with lower MGH1 levels as compared to being Haitian American with diabetes (B=-0.334, p=0.016). The findings suggest that methylglyoxal may be linked to hyperglycemia and metabolic changes in type 2 diabetes, and may differently impact the development of diabetes across Black subgroups.